Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study

BACKGROUND: Some prospective studies have shown that second‐generation tyrosine kinase inhibitors (TKIs) provide better control in patients with non‐small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations. However, studies comparing second‐line chemotherapy eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chien‐Yu, Hu, Chia‐Hao, Hsu, Chia‐Fu, Tsai, Jeng‐Shiuan, Chen, Chian‐Wei, Lin, Chia‐Yin, Chang, Chao‐Chun, Yen, Yi‐Ting, Tseng, Yau‐Lin, Su, Po‐Lan, Lin, Chien‐Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317592/
https://www.ncbi.nlm.nih.gov/pubmed/37183851
http://dx.doi.org/10.1111/1759-7714.14930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317592/
https://www.ncbi.nlm.nih.gov/pubmed/37183851
http://dx.doi.org/10.1111/1759-7714.14930

Ejemplares similares